Login
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE

viridiantherapeutics.com

What Do They Do?

Develops medicines for autoimmune and rare diseases, including treatments for thyroid eye disease and antibody-based therapies for other autoimmune disorders.

Who Are Their Customers?

Its business customers are companies that license rights to product candidates or work with Viridian on research and development; its future medicines are intended for patients with autoimmune and rare diseases.

Do Revenues Turn Into Profits?

No. It lost $342.6M in FY2025.

Operating income, FY2025
−513% of revenue
▼ −22% (Loss) vs FY2024 (−$299M, −99018%)
Net income, FY2025
−484% of revenue
▼ −27% (Loss) vs FY2024 (−$269.9M, −89387%)
Free cash flow, FY2025
−391% of revenue
▼ −19% (Loss) vs FY2024 (−$232.8M, −77096%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −64%
vs $70.6M in Q3 FY2025
Net income
▼ −193% (Loss)
vs −$34.6M in Q3 FY2025
License revenue share of revenue vs 99.2% in Q3 FY2025
  • Nov 9, 2026 VRDN-008 results prompted plans for pivotal trials in myasthenia gravis. The company plans to begin a pivotal trial in mid-2027, pending regulatory feedback, and focus its FcRn program on VRDN-008.
  • Jun 26, 2026 FDA approved Lumvoa for thyroid eye disease, and Viridian launched it. Lumvoa is approved for thyroid eye disease regardless of activity or duration.

From development to commercialization The older report described Viridian as discovering and developing medicines; the latest report adds commercialization and says the company is preparing its sales, market access, patient services, and commercial operations.

Expanded disease programs The older report centered on thyroid eye disease and described other rare-disease programs without naming their targets; the latest report also describes FcRn inhibitors for autoimmune disorders and a TSHR program for thyroid eye disease and Graves’ disease.

Revenue over time
Collaboration License
$100M$50M$0

Who Do They Compete With?

Competes with Amgen, Immunovant, Roche, Sling Therapeutics, Novartis, Lassen Therapeutics, Alumis, Argenx, UCB, Johnson and Johnson, GenSci, and AV7

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support